Application of compound radix salviae miltiorrhizae preparation to preparation of pulmonary arterial hypertension resisting medicaments

A technology of pulmonary arterial hypertension and compound salvia miltiorrhiza, applied in the field of medicine, can solve problems such as unreported effects

Active Publication Date: 2012-05-30
TIANJIN TASLY PHARMA CO LTD
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report about the effect of compound Dan

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound radix salviae miltiorrhizae preparation to preparation of pulmonary arterial hypertension resisting medicaments
  • Application of compound radix salviae miltiorrhizae preparation to preparation of pulmonary arterial hypertension resisting medicaments
  • Application of compound radix salviae miltiorrhizae preparation to preparation of pulmonary arterial hypertension resisting medicaments

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0032] Experimental Example 1: Effects of Preadministration of Compound Danshen Dripping Pills on Monocrotaline-induced Pulmonary Hypertension in Rats.

[0033] Sixty SD rats were divided into 6 groups, 10 in each group. The model group and each administration group were given a one-time intraperitoneal injection of 2% MCT (configured with ethanol and normal saline according to the volume ratio of 2:8) to replicate the rat pulmonary hypertension model at 60 mg / kg, and gavage was started on the second day after the model was established. medication. Animals in each group were administered intragastrically, once a day, for one month continuously. After the administration, 6-8 rats were taken from each group to measure the pulmonary artery pressure. After measuring the pulmonary artery pressure, the heart, liver and lungs were taken out and weighed. Weigh the weight of the right ventricle and perform ratio conversion. The right lung was taken for pathological examination. Th...

experiment example 2

[0043] Experimental Example 2: The effect of preadministration of Compound Danshen Dripping Pills on pulmonary hypertension in rats induced by hypobaric oxygen chambers.

[0044] 56 SD rats were divided into 5 groups, 8 in each group. The hypoxia model group, hypoxia + compound dandi low group, hypoxia + compound dandi high group, hypoxia + sildenafil group adopted intermittent hypobaric hypoxic method, and rats were placed in hypobaric hypoxic In the cabin, close the hatch door and open the pump door. When the pressure in the cabin drops to about 380mmH, the oxygen concentration remains at about 10.0±0.5%, which is equivalent to the oxygen concentration in the air at an altitude of 5000-5500m. Adjust the intake valve so that the speed of the gas entering and exiting is consistent and the pressure in the cabin is kept stable. Once a day, each time for 6 hours, for three consecutive weeks of hypoxia. Animals were administered orally once a day for three weeks.

[0045] After...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of pharmaceuticals and relates to application of a compound radix salviae miltiorrhizae preparation to preparation of pulmonary arterial hypertension resisting medicaments. According to the application disclosed by the invention, monocrotaline and a low-pressure oxygen cabin are utilized for reproducing a pulmonary arterial hypertension model on a rat, treatment and administration are performed through compound radix salviae miltiorrhizae dripping pills, and experimental data indicates that the compound radix salviae miltiorrhizae can significantly reduce the pulmonary arterial hypertension of a model animal, show a good effect of resisting pulmonary arterial vascular proliferation in pathology and improve the pulmonary arterial ring relaxation of the animal with the pulmonary arterial hypertension. The compound radix salviae miltiorrhizae dripping pills can be used as an ideal medicament for preventing and treating the pulmonary arterial hypertension and other related diseases.

Description

Technical field: [0001] The invention belongs to the field of medicine, and in particular relates to the application of compound salvia miltiorrhiza preparation in the preparation of anti-pulmonary hypertension medicine. Background technique: [0002] Pulmonary arterial hypertension (PAH) is a disease characterized by vasospasm, intimal hyperplasia and remodeling of pulmonary arterioles. The combined effects of vasoconstriction, vascular wall remodeling and in situ thrombus formation lead to a progressive increase in pulmonary vascular resistance, eventually leading to right heart failure and death. It is a progressive disease with a poor prognosis. treatment plan. [0003] The treatment of pulmonary arterial hypertension mainly adopts traditional therapy: including oral calcium channel blockers, anticoagulants, diuretics and oxygen inhalation, and the average survival time is <3 years. In recent years, the research on the mechanism of pulmonary hypertension has develop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/537A61P9/12A61P11/00
CPCA61K36/537A61K31/045A61K36/258A61P9/00A61P9/04A61P9/12A61P11/00
Inventor 朱永宏李欣欣马晓慧马洁周王谊莫红梅
Owner TIANJIN TASLY PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap